Structure Therapeutics (NASDAQ:GPCR) Price Target Cut to $97.00 by Analysts at Citigroup

Structure Therapeutics (NASDAQ:GPCR) had its target price lowered by Citigroup from $100.00 to $97.00 in a report published on Friday morning,Benzinga reports. Citigroup currently has a buy rating on the stock.

Other equities research analysts have also recently issued research reports about the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Structure Therapeutics in a research note on Friday, July 17th. Wall Street Zen upgraded Structure Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday, August 1st. Canaccord Genuity Group set a $111.00 price target on shares of Structure Therapeutics in a research report on Friday. HC Wainwright decreased their price target on shares of Structure Therapeutics from $100.00 to $70.00 and set a “buy” rating for the company in a research note on Thursday, June 11th. Finally, Citizens Jmp dropped their price objective on shares of Structure Therapeutics from $113.00 to $110.00 and set a “market outperform” rating on the stock in a research note on Friday. Three research analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $110.91.

Structure Therapeutics Price Performance

Shares of Structure Therapeutics stock opened at $53.14 on Friday. Structure Therapeutics has a one year low of $15.86 and a one year high of $94.90. The stock’s 50-day moving average is $47.63 and its 200 day moving average is $54.19. The firm has a market cap of $3.78 billion, a price-to-earnings ratio of -53.14 and a beta of -1.43.

Structure Therapeutics (NASDAQ:GPCR) last issued its earnings results on Thursday, August 6th. The company reported ($0.49) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.10). On average, sell-side analysts expect that Structure Therapeutics will post -1.64 EPS for the current fiscal year.

Institutional Investors Weigh In On Structure Therapeutics

Several institutional investors have recently bought and sold shares of GPCR. Morgan Stanley grew its position in Structure Therapeutics by 261.4% in the 4th quarter. Morgan Stanley now owns 2,087,834 shares of the company’s stock worth $145,209,000 after purchasing an additional 1,510,093 shares in the last quarter. Wellington Management Group LLP grew its stake in Structure Therapeutics by 25.2% in the 4th quarter. Wellington Management Group LLP now owns 7,121,984 shares of the company’s stock valued at $495,334,000 after purchasing an additional 1,432,797 shares during the period. Price T Rowe Associates Inc. MD increased its position in shares of Structure Therapeutics by 477.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,671,138 shares of the company’s stock valued at $116,228,000 after purchasing an additional 1,381,745 shares during the last quarter. Avoro Capital Advisors LLC raised its stake in shares of Structure Therapeutics by 21.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 6,555,555 shares of the company’s stock worth $455,939,000 after purchasing an additional 1,150,000 shares during the period. Finally, Capitolis Liquid Global Markets LLC bought a new stake in shares of Structure Therapeutics during the 4th quarter worth $61,086,000. Institutional investors own 91.78% of the company’s stock.

About Structure Therapeutics

Structure Therapeutics (NASDAQ:GPCR) is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.